Stock PPBT PURPLE BIOTECH LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Purple Biotech Ltd. TEL AVIV STOCK EXCHANGE

Equities

PPBT

IL0007650166

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Purple Biotech : Immediate report on other matter
PU
Purple Biotech : Immediate Report
PU
Purple Biotech : Immediate Report
PU
Purple Biotech : Report Of Foreign Private Issuer Form 6 K
PU
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise
MT
Purple Biotech : Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
PU
Purple Biotech Ltd. Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
CI
Purple Biotech : Immediate Report of Meeting
PU
Purple Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Form 6 K
PU
6K: The Tel Aviv District Court dismissed the previously disclosed lawsuit and motion to approve the lawsuit as a class action lawsuit which was filed against us, our executive directors and certain of our present and former directors in February 2017
PU
Purple Biotech : Immediate Report
PU
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
AQ
Purple Biotech Ltd Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and Other Efficacy Endpoints in Pancreatic Cancer
CI
Purple Biotech Reports First Quarter 2024 Financial Results
AQ
Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
CI
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
AQ
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology
CI
Purple Biotech : Immediate Report
PU
6K:Fourth Quarter and Full-Year 2023 Financial Results
PU
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PPBT Stock
  4. PPBT Stock
  5. News Purple Biotech Ltd.